Patents by Inventor Jeremy Duffield
Jeremy Duffield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11427561Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.Type: GrantFiled: January 18, 2017Date of Patent: August 30, 2022Assignee: BIOGEN MA INC.Inventors: Timothy Chan, Kevin M. Guckian, Tracy Jenkins, Jermaine Thomas, Jeffrey Vessels, Gnanasambandam Kumaravel, Robert Meissner, Joseph P. Lyssikatos, Brian Lucas, Irina Leaf, Jeremy Duffield, Nathan Genung
-
Publication number: 20220098582Abstract: Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.Type: ApplicationFiled: July 2, 2021Publication date: March 31, 2022Applicant: SanofiInventors: Jeremy Duffield, Balkrishen Bhat, Deidre MacKenna
-
Publication number: 20210188809Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.Type: ApplicationFiled: January 18, 2017Publication date: June 24, 2021Inventors: Timothy Chan, Kevin Guckian, Tracy Jenkins, Jermaine Thomas, Jeffrey Vessels, Gnanasambandam Kumaravel, Robert Meissner, Joseph P. Lyssikatos, Brian Lucas, Irina Leaf, Jeremy Duffield, Nathan Genung
-
Publication number: 20200283765Abstract: Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.Type: ApplicationFiled: January 21, 2020Publication date: September 10, 2020Applicant: SanofiInventors: Jeremy Duffield, Balkrishen Bhat, Deidre MacKenna
-
Patent number: 10577367Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.Type: GrantFiled: February 8, 2019Date of Patent: March 3, 2020Assignee: BIOGEN MA INC.Inventors: Timothy Chan, Kevin Guckian, Tracy Jenkins, Jermaine Thomas, Jeffery Vessels, Gnanasambandam Kumaravel, Robert Meissner, Joseph Lyssikatos, Brian Lucas, Irina Leaf, Jeremy Duffield
-
Publication number: 20190248787Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.Type: ApplicationFiled: February 8, 2019Publication date: August 15, 2019Inventors: Timothy Chan, Kevin Guckian, Tracy Jenkins, Jermaine Thomas, Jeffery Vessels, Gnanasambandam Kumaravel, Robert Meissner, Joseph Lyssikatos, Brian Lucas, Irina Leaf, Jeremy Duffield
-
Patent number: 10246456Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.Type: GrantFiled: July 17, 2015Date of Patent: April 2, 2019Assignee: BIOGEN MA INC.Inventors: Timothy Chan, Kevin Guckian, Tracy Jenkins, Jermaine Thomas, Jeffery Vessels, Gnanasambandam Kumaravel, Robert Meissner, Joseph Lyssikatos, Brian Lucas, Irina Leaf, Jeremy Duffield
-
Publication number: 20180298385Abstract: Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.Type: ApplicationFiled: April 9, 2018Publication date: October 18, 2018Applicant: Regulus Therapeutics Inc.Inventors: Jeremy Duffield, Balkrishen Bhat, Deidre MacKenna
-
Patent number: 9970011Abstract: Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.Type: GrantFiled: May 26, 2017Date of Patent: May 15, 2018Assignee: Regulus Therapeutics Inc.Inventors: Jeremy Duffield, Balkrishen Bhat, Deidre MacKenna
-
Publication number: 20170369879Abstract: Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.Type: ApplicationFiled: May 26, 2017Publication date: December 28, 2017Applicant: Regulus Therapeutics Inc.Inventors: Jeremy Duffield, Balkrishen Bhat, Deidre MacKenna
-
Patent number: 9751923Abstract: The present disclosure provides molecules, compositions and methods for treating scarring in organs. The molecules, compositions and methods treat scarring by modulating the WNT, platelet-derived growth factor receptor (PDGFR), transforming growth factor-beta (TGF3) and/or connective-tissue growth factor (CTGF) signaling pathways.Type: GrantFiled: November 1, 2013Date of Patent: September 5, 2017Assignee: University of Washington Through Its Center For CommercializationInventors: Jeremy Duffield, Shuyu Ren, Rashmi Hedge
-
Publication number: 20170204093Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.Type: ApplicationFiled: July 17, 2015Publication date: July 20, 2017Inventors: Timothy Chan, Kevin Guckian, Tracy Jenkins, Jermaine Thomas, Jeffery Vessels, Gnanasambandam Kumaravel, Robert Meissner, Joseph Lyssikatos, Brian Lucas, Irina Leaf, Jeremy Duffield
-
Patent number: 9688986Abstract: Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.Type: GrantFiled: May 10, 2016Date of Patent: June 27, 2017Assignee: Regulus Therapeutis Inc.Inventors: Jeremy Duffield, Balkrishen Bhat, Deidre MacKenna
-
Publication number: 20160319283Abstract: Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.Type: ApplicationFiled: May 10, 2016Publication date: November 3, 2016Inventors: Jeremy Duffield, Balkrishen Bhat, Deidre MacKenna
-
Patent number: 9359609Abstract: Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.Type: GrantFiled: April 2, 2015Date of Patent: June 7, 2016Assignee: Regulus Therapeutics Inc.Inventors: Jeremy Duffield, Balkrishen Bhat, Deidre MacKenna
-
Publication number: 20150337021Abstract: The present disclosure provides molecules, compositions and methods for treating scarring in organs. The molecules, compositions and methods treat scarring by modulating the WNT, platelet-derived growth factor receptor (PDGFR), transforming growth factor-beta (TGF3) and/or connective-tissue growth factor (CTGF) signaling pathways.Type: ApplicationFiled: November 1, 2013Publication date: November 26, 2015Inventors: Jeremy Duffield, Shuyu Ren, Rashmi Hedge
-
Publication number: 20150299704Abstract: Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.Type: ApplicationFiled: April 2, 2015Publication date: October 22, 2015Inventors: Jeremy Duffield, Balkrishen Bhat, Deidre MacKenna
-
Patent number: 9012423Abstract: Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.Type: GrantFiled: October 8, 2013Date of Patent: April 21, 2015Assignee: Regulus Therapeutics Inc.Inventors: Jeremy Duffield, Balkrishen Bhat, Deidre MacKenna
-
Patent number: 8703708Abstract: Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.Type: GrantFiled: March 18, 2010Date of Patent: April 22, 2014Assignees: The Brigham and Women's Hospital, Inc., Cincinnati Children's Hospital Medical CenterInventors: Jeremy Duffield, Richard A. Lang
-
Publication number: 20140100263Abstract: Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome.Type: ApplicationFiled: October 8, 2013Publication date: April 10, 2014Applicant: REGULUS THERAPEUTICS INC.Inventors: Jeremy Duffield, Balkrishen Bhat, Deidre MacKenna